Central Medical Affairs
Frankfurt am Main, 60318, Germany
NCT Number: NCT00624026
The study objective is to evaluate the effects of memantine treatment on communication abilities and other cognitive abilities in moderate to severe DAT patients.
Looking for future studies?
Notify Me50 year–90 year
All sexes
Interventional
Phase 3
Frankfurt am Main, 60318, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
20 mg per day (once daily)
Time frame: 4 months
Merz Pharmaceuticals GmbH
Industry
Prospective, Single-arm, Multicenter, Open-label Study to Investigate the Efficacy and Tolerability of the Once Daily (OD) Memantine Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05519137
Alzheimer Disease, Alzheimer's Disease
Menands, New York, United States
View Trial DetailsNCT04867616
Alzheimer Disease, Alzheimer's Disease
Fresno, California, United States
View Trial DetailsNCT02947893
Alzheimer Disease, Alzheimer's Disease
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06206824
Abnormalities, Multiple, Alzheimer Disease
Gières, France
View Trial Details